Omnitrope (somatropin [rDNA
origin])
Information
FDA approves Omnitrope (somatropin [rDNA origin]) for the
long-term treatment of pediatric patients who have growth failure
due to an inadequate secretion of endogenous growth hormone and for
long-term replacement therapy in adults with growth hormone
deficiency of either childhood or adult-onset etiology.
Back
to Top
Back to Drug Index
PDF requires the free Adobe
Acrobat Reader
Date created: May 30, 2006, updated June 21, 2006 |